Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (Anti-CTLA-4) Humanized Monoclonal Antibody (MDX-CTLA-4 NSC# 732442, Previously 720801) in Patients Previously Vaccinated With GM-CSF-Based Autologous Tumor Vaccines (CTEP Protocol Number P-5708) and Patients With Acute Myelogenous Leukemia/ Myelodysplasia, and Non-Small Cell Lung Cancer Who Have Not Received a Prior Vaccine
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- 31 Oct 2007 Status change from recruiting to in progress.
- 02 Nov 2005 New trial record.